EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Pharmacovigilance in Oncology: A Systematic Review on Monitoring the Safety and Adverse Drug Reactions of Anticancer Therapies

V. Madhavi, K. Dharani, J. Bhargavi, C. Mohana

International Journal of Scientific Research in Science and Technology · 23.05.2026 · 13 (3) · 370-375

DOI: 10.32628/ijsrst26133148 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Scientific Research in Science and Technology, online erschienen am 23.05.2026. Verfasst von V. Madhavi und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer remains a major global health challenge, with cases projected to reach 22.2 million annually by 2030. In India, over 1.46 million new cases were reported in 2022. Although multimodal treatments such as chemotherapy, targeted therapy, and immunotherapy have improved survival, they are often associated with significant adverse drug reactions (ADRs), necessitating strong pharmacovigilance systems.

Objective

To review cancer epidemiology, evaluate treatment-related ADR patterns, and highlight the importance of pharmacovigilance in oncology.

Methods

A comprehensive review of oncological safety data was conducted, focusing on incidence, patient demographics, ADR patterns, causality, severity, and reporting practices among healthcare professionals.

Results

Cancer incidence is slightly higher in males, but ADRs are more frequently reported in females (66.4%) and patients over 50 years. Breast and ovarian cancers are most commonly associated with ADRs. Most reactions occur during drug infusion, especially with platinum compounds and taxanes. Skin and respiratory systems are frequently affected. The majority of ADRs are moderate and classified as “probable.” Nurses contribute most ADR reports, while physician reporting remains minimal.

Conclusion

Underreporting of ADRs is a major challenge in oncology pharmacovigilance. Improving multidisciplinary reporting, increasing awareness, and integrating AI and electronic health records are essential to enhance drug safety and patient outcomes.

Zitieren

APA

Madhavi, V., Dharani, K., Bhargavi, J., & Mohana, C. (2026). Pharmacovigilance in Oncology: A Systematic Review on Monitoring the Safety and Adverse Drug Reactions of Anticancer Therapies. International Journal of Scientific Research in Science and Technology, 13(3), 370-375. https://doi.org/10.32628/ijsrst26133148

Vancouver

Madhavi V, Dharani K, Bhargavi J, Mohana C. Pharmacovigilance in Oncology: A Systematic Review on Monitoring the Safety and Adverse Drug Reactions of Anticancer Therapies. International Journal of Scientific Research in Science and Technology. 2026;13(3):370-375. doi:10.32628/ijsrst26133148

BibTeX
@article{Madhavi2026,
  author = {Madhavi, V. and Dharani, K. and Bhargavi, J. and Mohana, C.},
  title = {Pharmacovigilance in Oncology: A Systematic Review on Monitoring the Safety and Adverse Drug Reactions of Anticancer Therapies},
  journal = {International Journal of Scientific Research in Science and Technology},
  year = {2026},
  volume = {13},
  number = {3},
  pages = {370--375},
  doi = {10.32628/ijsrst26133148}
}
Kostenlos starten →